Tag: Biologics and Biosimilars Naming

The Time is Right for Canada to Incorporate a Naming Convention for Biologics and Biosimilars into its Emerging ePrescribing Infrastructure

By Pooja Babbrah, Senior Consultant In January 2017, the Food and Drug Administration (FDA) released the Final Rule for Biosimilar Naming. In this final rule, the FDA spelled out the …

How Stakeholders are Affected by FDA’s New Naming Convention for Biologics and Biosimilars

By Pooja Babbrah, Senior Consultant Stakeholders across the industry are debating potential costs and burden associated with implementing the new, nonproprietary naming convention for biologics and biosimilars. Requirements for the …